<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Gauvreau, Gail M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Novel AMG 157 Improved Inflammation and Bronchoconstriction in Allergic Asthma</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-10</style></pages><abstract><style  face="normal" font="default" size="100%">AMG 157 is a human antithymic stromal lymphopoietin (TSLP) monoclonal immunoglobulin-2? molecule that blocks the interaction between TSLP and its receptor, a process that is thought to be important in initiating allergic inflammation. This article presents data from the Double-Blind, Multiple Dose Study in Subjects With Mild Atopic Asthma study [NCT01405963; Gauvreau GM et al. Am J Crit Care Med 2014].</style></abstract><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>